Drug resistance is still one of the most important impediments to successful cancer treatment. The session "Drug Resistance" is dedicated to the exploration of mechanisms for cancer cell resistance to therapy and developing ways to overcome them.
Cancer cells can become resistant to therapy by various mechanisms, including genetic mutations, epigenetic alterations, activation of alternate signaling pathways, and selection due to the tumor microenvironment. Efflux pumps, DNA repair processes, and evasion from the immune system are also responsible for therapeutic resistance. Unraveling these mechanisms is essential for creating interventions that regain drug sensitivity and enhance patient outcomes.
This session discusses new strategies for counteracting drug resistance, such as combination regimens, targeted drugs, immunotherapy, and adaptive treatment protocols. Biomarker-based strategies and molecular profiling enable clinicians to identify resistant cell populations early and change therapy accordingly. Research is also revealing new compounds and methods to sidestep resistance mechanisms.
Participants will learn about the biology, clinical relevance, and new therapeutic approaches to drug resistance in cancer. This session highlights the need to understand and address resistance as a key to more effective treatment, prevention of relapse, and development of long-lasting, individualized cancer therapies.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
